Thalassemia is diagnosed through a combination of blood tests, starting with a routine complete blood count and confirmed with specialized hemoglobin analysis or genetic testing. Most cases are first suspected when blood work reveals unusually small red blood cells, and the full diagnostic process can typically be completed within a few days to a couple of weeks depending on which tests are needed.
The First Step: Complete Blood Count
A standard complete blood count (CBC) is usually the first test that raises suspicion. The key marker is mean corpuscular volume (MCV), which measures the average size of your red blood cells. In thalassemia, red blood cells are consistently smaller than normal, a feature called microcytosis. An MCV below 80 femtoliters in adults is the typical flag.
What makes thalassemia stand out on a CBC is the combination of small red blood cells with a normal or even high red blood cell count. Your bone marrow is producing plenty of cells; they’re just smaller and carry less hemoglobin than they should. A blood smear viewed under a microscope may also show pale-looking red blood cells (hypochromia) and “target cells,” which have a bull’s-eye appearance. These features together create a pattern that points toward thalassemia rather than other causes of small red blood cells.
Ruling Out Iron Deficiency
Iron deficiency is the other common reason for small red blood cells, and distinguishing it from thalassemia matters because the treatments are completely different. Iron supplements help iron deficiency but do nothing for thalassemia, and unnecessary iron supplementation in someone with thalassemia can actually cause harm over time.
Your doctor will typically order iron studies alongside or shortly after the CBC. A ferritin level below 20 micrograms per deciliter suggests iron deficiency as the cause of small red blood cells. If ferritin is normal or high, thalassemia becomes more likely. In some cases, both conditions exist at the same time, which complicates the picture and may require iron treatment first before thalassemia can be properly confirmed.
A simple calculation called the Mentzer Index can also help sort this out. It divides your MCV by your red blood cell count. A result below 13 suggests thalassemia, while a result above 13 leans toward iron deficiency. The logic is straightforward: in iron deficiency, your body makes fewer red blood cells and they’re small, pushing the ratio higher. In thalassemia, your body makes a normal number of cells but they’re small, keeping the ratio low. This isn’t definitive on its own, but it helps guide the next steps.
Hemoglobin Analysis: The Confirmatory Test
The test that typically confirms a thalassemia diagnosis is hemoglobin analysis, done through either hemoglobin electrophoresis or a technique called high-performance liquid chromatography (HPLC). Both methods separate the different types of hemoglobin in your blood and measure their proportions. The combined sensitivity and specificity of these methods is approximately 99%.
Normal adult hemoglobin is mostly type A, with small amounts of types A2 and F (fetal hemoglobin). In beta-thalassemia trait (the carrier state), hemoglobin A2 rises above 3.7%, while hemoglobin A drops slightly to 92 to 95%. Fetal hemoglobin may be mildly elevated at 1 to 4%. In beta-thalassemia major, the most severe form, hemoglobin A is absent entirely, and fetal hemoglobin makes up 95 to 100% of the total. These distinct patterns make hemoglobin analysis a reliable way to identify both carriers and people with more serious disease.
One important limitation: these tests can give misleading results if you’ve had a recent blood transfusion, since donor blood changes the hemoglobin proportions in your sample. If you’ve been transfused, your doctor may need to wait or use genetic testing instead.
Genetic Testing for Alpha-Thalassemia
Alpha-thalassemia is harder to detect with hemoglobin analysis alone because the hemoglobin pattern often looks normal in carriers. This is where DNA-based testing becomes essential. A genetic screen looks directly at the two genes responsible for alpha-globin production (HBA1 and HBA2) and identifies whether any copies are missing or mutated.
About 95% of all alpha-thalassemia is caused by gene deletions that genetic testing can detect. The most common single-gene deletions are the 3.7 kilobase and 4.2 kilobase types, where one of the four alpha-globin gene copies is missing. Larger deletions remove two genes from the same chromosome, and these are named by the populations where they’re most common: Southeast Asian, Filipino, Thai, and Mediterranean types. Knowing which specific deletion you carry matters, because two-gene deletions on the same chromosome carry a higher risk of severe disease in future children than two single-gene deletions on separate chromosomes.
Genetic testing is also the method used for expanded carrier screening, which can identify carriers of both alpha and beta-thalassemia along with other inherited blood disorders in a single panel.
Screening During Pregnancy
The American College of Obstetricians and Gynecologists recommends offering universal hemoglobinopathy testing to anyone planning a pregnancy or at their first prenatal visit, if no prior results are available. This replaced older guidelines that screened based on race and ethnicity. The shift reflects the reality that roughly 1 in 66 people in the United States carries a hemoglobinopathy trait, and self-identified ethnicity is a poor proxy for genetic ancestry.
Screening can be done with hemoglobin electrophoresis or molecular genetic testing. If both parents are found to be carriers, prenatal diagnosis of the fetus becomes an option. Chorionic villus sampling (CVS) can be performed at 10 to 12 weeks of pregnancy, making it the preferred method for early diagnosis. Amniocentesis is an alternative in the second trimester. Both procedures collect fetal cells for DNA analysis to determine whether the baby has inherited thalassemia trait, thalassemia disease, or no thalassemia at all.
Newborn Screening
Most states include hemoglobinopathy testing in their standard newborn screening panels. A small blood sample taken from the baby’s heel is analyzed using the same HPLC or electrophoresis methods used in adults. Newborn screening reliably picks up beta-thalassemia major because affected infants have very high levels of fetal hemoglobin and no hemoglobin A. Alpha-thalassemia and beta-thalassemia trait are harder to detect at birth and may require follow-up testing as the child grows.
What the Results Mean in Practice
If your CBC shows small red blood cells and your hemoglobin analysis comes back with elevated hemoglobin A2, you most likely carry beta-thalassemia trait. This is not a disease. Carriers typically feel fine and need no treatment, but the information is valuable for family planning. If your partner also carries a thalassemia gene, each pregnancy carries a 25% chance of producing a child with thalassemia major.
If testing reveals thalassemia intermedia or major, the severity determines what comes next. People with thalassemia major are usually diagnosed in the first two years of life when fetal hemoglobin naturally declines and severe anemia develops. Thalassemia intermedia falls somewhere in between, with symptoms ranging from mild to moderate anemia that may or may not require regular transfusions. In all cases, the reticulocyte count, which measures how actively your bone marrow is producing new red blood cells, is typically normal or only slightly elevated in thalassemia trait, while it may be higher in more severe forms as the body tries to compensate for anemia.
The full testing sequence, from initial CBC to confirmed diagnosis, is straightforward and widely available. If your doctor suspects thalassemia based on routine blood work, hemoglobin analysis or genetic testing will give you a clear answer, usually within one to two weeks.